Cargando…

Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer

OBJECTIVE: Colonic mucosa-associated Escherichia coli are increased in Crohn's disease (CD) and colorectal cancer (CRC). They variously haemagglutinate, invade epithelial cell lines, replicate within macrophages, translocate across M (microfold) cells and damage DNA. We investigated genes respo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prorok-Hamon, Maelle, Friswell, Melissa K, Alswied, Abdullah, Roberts, Carol L, Song, Fei, Flanagan, Paul K, Knight, Paul, Codling, Caroline, Marchesi, Julian R, Winstanley, Craig, Hall, Neil, Rhodes, Jonathan M, Campbell, Barry J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995253/ https://www.ncbi.nlm.nih.gov/pubmed/23846483 http://dx.doi.org/10.1136/gutjnl-2013-304739

Ejemplares similares

Hemidesmosome integrity protects the colon against colitis and colorectal cancer
por: De Arcangelis, Adèle, et al.
Publicado: (2017)

Outcomes of inflammatory bowel disease in patients with eosinophil-predominant colonic inflammation
por: Alhmoud, Tarik, et al.
Publicado: (2020)

Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis
por: van der Post, Sjoerd, et al.
Publicado: (2019)

Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism
por: Oancea, I, et al.
Publicado: (2017)

Faster and less invasive tools to identify patients with ileal colonization by adherent‐invasive E. coli in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Neurotensin—regulated miR-133α is involved in proinflammatory signalling in human colonic epithelial cells and in experimental colitis
por: Law, Ivy Ka Man, et al.
Publicado: (2015)

Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis
por: Johansson, Malin E V, et al.
Publicado: (2014)

Hyperbaric oxygen therapy stimulates colonic stem cells and induces mucosal healing in patients with refractory ulcerative colitis: a prospective case series
por: Bekheit, Mohamed, et al.
Publicado: (2016)

Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC
por: Starr, Amanda E, et al.
Publicado: (2017)

Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers
por: Roberts, Carol L, et al.
Publicado: (2010)

Genital warts and inflammatory bowel diseases: Danish real‐world evidence to assess patient‐relevant outcomes
por: McLellan, Paul, et al.
Publicado: (2022)

Perianal fistulizing Crohn's disease and overall risk of cancer: No red flag
por: McLellan, Paul, et al.
Publicado: (2023)

Abnormally expressed ER stress response chaperone Gp96 in CD favours adherent-invasive Escherichia coli invasion
por: Rolhion, Nathalie, et al.
Publicado: (2010)

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
por: Cornillie, Freddy, et al.
Publicado: (2014)

The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association
por: Kaplan, Gilaad G, et al.
Publicado: (2010)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis
por: Weisel, Kathy, et al.
Publicado: (2021)

A blood-based prognostic biomarker in IBD
por: Biasci, Daniele, et al.
Publicado: (2019)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: the Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale
por: Adegbola, Samuel O, et al.
Publicado: (2021)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)
por: Danese, Silvio, et al.
Publicado: (2019)

Eosinophil-mediated signalling attenuates inflammatory responses in experimental colitis
por: Masterson, Joanne C, et al.
Publicado: (2015)

IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology
por: Jones, Gareth-Rhys, et al.
Publicado: (2019)

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
por: Rutgeerts, Paul J, et al.
Publicado: (2013)

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
por: Panés, Julian, et al.
Publicado: (2017)

Impact of the coronavirus infectious disease (COVID-19) pandemic on the provision of inflammatory bowel disease (IBD) antenatal care and outcomes of pregnancies in women with IBD
por: Selinger, Christian Philipp, et al.
Publicado: (2021)

Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease
por: Koelink, Pim J, et al.
Publicado: (2014)

Use of complementary and alternative medicine and low quality of life associate with the need for psychological and psychotherapeutic interventions in inflammatory bowel disease
por: Kutschera, Maximilian, et al.
Publicado: (2021)

A novel unconventional T cell population enriched in Crohn’s disease
por: Rosati, Elisa, et al.
Publicado: (2022)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse
por: Arrieta, M C, et al.
Publicado: (2008)

Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition
por: Binion, D G, et al.
Publicado: (2008)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
por: Tursi, Antonio, et al.
Publicado: (2010)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis
por: Aherne, Carol M, et al.
Publicado: (2011)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
por: Travis, Simon P L, et al.
Publicado: (2011)

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
por: Cayatte, Corinne, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ujh2j2ga3jjuqvn3g9nugj7fjr